Search
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalRupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus. … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections.
TB-402
go.drugbank.com/drugs/DB06050InvestigationalTB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
MIV-701
go.drugbank.com/drugs/DB05736ExperimentalMIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
Butylphthalide
go.drugbank.com/drugs/DB12749InvestigationalButylphthalide has been used in trials studying the prevention of Restenosis.
Synonyms: 3-n-butylphthalide, DL-3-n-butylphthalideCategories: Compounds used in a research, industrial, or household settingPumactant
go.drugbank.com/drugs/DB04955ExperimentalPumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure